Drugs / GR1803
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07348055 | Feb 2026 → Jun 2027 expected | systemic lupus erythematosus | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07090954 | Aug 2025 → Jul 2026 overdue | plasma cell myeloma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07102706 | May 2022 → May 2025 | plasma cell myeloma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06952075 | Apr 2025 → Jul 2027 expected | plasma cell myeloma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06566547 | Aug 2024 → May 2027 expected | plasma cell myeloma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07452198 | Mar 2026 → Mar 2029 expected | plasma cell myeloma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GR1803 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06566547 ↗ |
| Route | Intravenous | “intravenous GR1803 injection” NCT07452198 ↗ |